Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 2, 2024 -- The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy is very low, according to a study published online Jan. 24 in Nature Medicine.
Guido Ghilardi, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues describe a case of T-cell lymphoma (TCL) occurring three months after CAR T-cell immunotherapy for non-Hodgkin B-cell lymphoma, which was diagnosed from a thoracic lymph node identified at lung cancer surgery. To assess the overall risk of secondary primary malignancy after commercial CART, 449 patients treated at the University of Pennsylvania were reviewed.
The researchers found that the CAR transgene was low, while the TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant. Before CART infusion, the T-cell clone was identified at low levels in the blood, and it was detected in the lung cancer. In the cohort of patients treated at the University of Pennsylvania, 3.6 percent had secondary primary malignancy at a median follow-up of 10.3 months. For solid and hematological malignancies, the median onset time was 26.4 and 9.7 months, respectively. The projected five-year cumulative incidence was 15.2 and 2.3 percent for solid and hematological malignancies.
"The observed very low incidence of secondary T-cell lymphomas should provide reassurance to the scientific community regarding the safety of commercially available CART products," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
Tattoos May Increase Risk of Malignant Lymphoma
WEDNESDAY, May 29, 2024 -- Tattoo exposure is associated with an increased risk of several malignant lymphoma subtypes, according to a study published online in the June issue...
Living Outside of Comprehensive Cancer Center Catchment Area Tied to Later-Stage Diagnosis
TUESDAY, May 28, 2024 -- Disadvantaged populations and those living outside of a comprehensive cancer center's main catchment area have higher odds of receiving a diagnosis of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.